Drug Type Bispecific antibody |
Synonyms Anti-PD-1/IL7v(OSE) |
Target |
Mechanism IL-7 inhibitors(interleukin 7 inhibitors), PD-1 inhibitors(Programmed cell death protein 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | FR | 17 Apr 2023 |